EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tumor‐Bearing Status Accelerates Bleomycin‐Induced Pulmonary Inflammation via Endothelial Activation

Shoko Isoyama, Kakuhiro Yamaguchi iD, Hiroshi Iwamoto, Yasushi Horimasu, Kunihiko Funaishi, Kiyofumi Shimoji, Shinjiro Sakamoto, Takeshi Masuda, Taku Nakashima, Shinichiro Ohshimo, Hironobu Hamada iD, Noboru Hattori iD

Thoracic Cancer · 2026-04 · 17 (7)

DOI: 10.1111/1759-7714.70272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 30.03.2026. Verfasst von Shoko Isoyama und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Bleomycin, Pneumonia, Carcinoma, Lewis Lung. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Drug‐induced lung disease (DILD) is a severe adverse event of cancer treatment. Several clinical reports have demonstrated an association between DILD and tumor progression. However, the underlying mechanism remains unclear. This study aimed to elucidate the role of tumor‐bearing status in the development of DILD.

Methods

We prepared a subcutaneous Lewis lung carcinoma (LLC) and KLN205‐bearing model. To trigger DILD, bleomycin (BLM) was administered subcutaneously. mRNA expression associated with endothelial activation (PAI‐1, vWF, and ICAM‐1), inflammatory cell infiltration, and alveolar wall thickness was assessed by using bronchioalveolar lavage fluid (BALF) and lung tissue. Additionally, the role of high‐mobility group box 1 (HMGB1) in tumor‐bearing status was examined.

Results

Compared with control mice, LLC‐ and KLN205‐bearing mice showed a tendency toward increased expression of at least one of PAI‐1, vWF, and ICAM‐1 on endothelium, along with inflammatory cell infiltration in the lungs. BLM‐treated mice with LLC showed more inflammatory cell infiltration than BLM‐treated mice, accompanied by a significant increase in PAI‐1, vWF, and ICAM‐1 expression on endothelium. Moreover, BLM‐treated mice with LLC exhibited pronounced alveolar wall thickening. In LLC‐bearing mice, serum HMGB1 levels were significantly higher compared with control mice. Additionally, inflammatory cell infiltration in the lungs tended to be increased by the intraperitoneal injection of HMGB1, which was accompanied by increased expression of vWF and ICAM‐1 on endothelium.

Conclusions

This study showed that tumor‐bearing status elicits proinflammatory activation in endothelial cells and inflammatory cell infiltration into the lungs that aggravates DILD caused by BLM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BleomycinPneumoniaCarcinoma, Lewis LungAnimalsMiceHMGB1 ProteinMice, Inbred C57BLMaleIntercellular Adhesion Molecule-1Disease Models, Animalvon Willebrand Factor

Stichwörter der Autor:innen

HMGB1drug‐induced lung diseaseendothelial cellsinflammationtumor

Substanzen

BleomycinHMGB1 ProteinIntercellular Adhesion Molecule-1von Willebrand Factor

Autor:innen und Institutionen

  • Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
  • Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.
  • Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
  • Department of Physical Analysis and Therapeutic Sciences, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.

ORCID-Profile: Kakuhiro Yamaguchi, Hironobu Hamada, Noboru Hattori

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Isoyama, S., Yamaguchi, K., Iwamoto, H., Horimasu, Y., Funaishi, K., Shimoji, K., Sakamoto, S., Masuda, T., Nakashima, T., Ohshimo, S., Hamada, H., & Hattori, N. (2026). Tumor‐Bearing Status Accelerates Bleomycin‐Induced Pulmonary Inflammation via Endothelial Activation. Thoracic Cancer, 17(7). https://doi.org/10.1111/1759-7714.70272

Vancouver

Isoyama S, Yamaguchi K, Iwamoto H, Horimasu Y, Funaishi K, Shimoji K, et al. Tumor‐Bearing Status Accelerates Bleomycin‐Induced Pulmonary Inflammation via Endothelial Activation. Thoracic Cancer. 2026;17(7). doi:10.1111/1759-7714.70272

BibTeX
@article{Isoyama2026,
  author = {Isoyama, Shoko and Yamaguchi, Kakuhiro and Iwamoto, Hiroshi and Horimasu, Yasushi and Funaishi, Kunihiko and Shimoji, Kiyofumi and Sakamoto, Shinjiro and Masuda, Takeshi and Nakashima, Taku and Ohshimo, Shinichiro and Hamada, Hironobu and Hattori, Noboru},
  title = {Tumor‐Bearing Status Accelerates Bleomycin‐Induced Pulmonary Inflammation via Endothelial Activation},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {7},
  doi = {10.1111/1759-7714.70272}
}
Kostenlos starten →